A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
- NCT ID
- NCT07816198
- Registry status
- Not yet recruiting
- Study type
- Not specified in the registry data
- Phase
- Phase 3
- Sponsor
- Addpharma Inc.
Overview
ClinicalTrials.gov lists this study as Not yet recruiting.
Enrollment: 354 participants (Estimated).
What is being studied
No interventions are listed in the registry data.
Who may be eligible
- Ages
- Not specified in the registry data
- Sex
- Not specified in the registry data
- Healthy volunteers accepted
- No
ClinicalTrials.gov lists the following eligibility criteria.
Inclusion Criteria:
* Signed informed consent
* Other inclusions applied
Exclusion Criteria:
* Subjects with severe diabetic complications
* Other exclusions applied
Study locations
No study locations are listed in the registry data.
Study details
- Start date
- September 30, 2026
- Primary completion date
- June 30, 2028
- First posted
- September 11, 2026
Source and update information
- Source
- ClinicalTrials.gov
- NCT ID
- NCT07816198
- Registry last updated
- September 16, 2026
- QualifiedStudies registry data refreshed
- September 21, 2026
View NCT07816198 on ClinicalTrials.gov
Trial information can change. Confirm current study details with the study team or the registry.
About joining clinical research
Find clinical trials you may match with
QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.
Find clinical trials you may match with | Diabetes (Type II) studies | Clinical trial FAQ